Premium
Narrow‐band ultraviolet therapy in early‐stage mycosis fungoides: study on 20 patients
Author(s) -
Brazzelli V.,
Antoninetti M.,
Palazzini S.,
Prestinari F.,
Borroni G.
Publication year - 2007
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/j.1600-0781.2007.00314.x
Subject(s) - mycosis fungoides , stage (stratigraphy) , medicine , dermatology , ultraviolet b , surgery , lymphoma , paleontology , biology
Background: In recent years, narrow‐band ultraviolet B (NB‐UVB, 311–313 nm) has been found to be beneficial for early‐stages mycosis fungoides (MF). The aim of this study is to investigate the effect of NB‐UVB in 20 patients with early‐stage MF. Methods: Twenty patients (10 women and 10 men, mean age 54 ± 22 years) with clinically and histologically confirmed MF were enrolled in the study. All of the patients had clinical stage I disease (T1 or T2, N0, M0) with cutaneous involvement, consisting of patch‐stage disease of limited extent, in 50% of the cases (stage IA), and more widespread in the other 50% (stage IB). All the patients were treated with NB‐UVB therapy until more than 95% clearance of the patient's skin lesions had occurred. Results: A complete response was achieved in 90% of the cases after a mean of 29 ± 14 treatments within a mean period of 4 months (range 1–8 months), with an average cumulative dose of 25 ± 16.77 J/cm 2 . In the follow‐up period, relapse occurred after a mean period of 8 months (range 3–17 months), and then therapy was restarted. Conclusion: This study provides evidence that NB‐UVB might be an efficient option for stage IA and IB MF patients.